Zhen Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zhen Luo has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Bee-Chun Sun
10 shared publicationsBing Wan
10 shared publications- Christopher W. Szeto
Small Molecule Discovery, Exelixis Inc, Alameda, USA
10 shared publications - David I. Bellovin
Biologics Discovery, Zai Lab (US) LLC, Menlo Park, California
10 shared publications - Hiroyasu Konno
Zai Lab (US) LLC, Menlo Park, California
10 shared publications - John Zhang
Zai Lab (Shanghai) Co., Ltd. Pudong, Shanghai, P.R. China
10 shared publications
Latest Publications
- 10 June 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (11) , e213627
Teaching NeuroImage: Differentiating Radiation-Induced Brain Injury and Tumor Recurrence
- 10 June 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (11) , e213627
Teaching NeuroImage: Differentiating Radiation-Induced Brain Injury and Tumor Recurrence
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell–mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models
Supplementary Figure 1 shows characterization of ZL-1211.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell–mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models
Supplementary Figure 1 shows characterization of ZL-1211.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell–mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models
Supplementary Figure 5 shows IHC for gastric PDX models with anti-CLDN18.2, human IgG, or NKp46 antibody.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell–mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models
Supplementary Figure 5 shows IHC for gastric PDX models with anti-CLDN18.2, human IgG, or NKp46 antibody.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell–mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models
Supplementary Figure 4 shows confirmation of NK depletion by flow cytometer and NK levels in spleen of the mouse models.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell–mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models
Supplementary Figure 4 shows confirmation of NK depletion by flow cytometer and NK levels in spleen of the mouse models.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell–mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models
Supplementary Figure 5 shows IHC for gastric PDX models with anti-CLDN18.2, human IgG, or NKp46 antibody.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell–mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models
Supplementary Figure 5 shows IHC for gastric PDX models with anti-CLDN18.2, human IgG, or NKp46 antibody.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell–mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models
Supplementary Figure 1 shows characterization of ZL-1211.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell–mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models
Supplementary Figure 1 shows characterization of ZL-1211.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell–mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models
Supplementary Figure 4 shows confirmation of NK depletion by flow cytometer and NK levels in spleen of the mouse models.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell–mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models
Supplementary Figure 4 shows confirmation of NK depletion by flow cytometer and NK levels in spleen of the mouse models.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell–mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models
Supplementary Figure 3 shows CLDN18.2 expression in gastric tumor cell lines and ZL-1211-induced CDC for the gastric tumor cell lines.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell–mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models
Supplementary Figure 3 shows CLDN18.2 expression in gastric tumor cell lines and ZL-1211-induced CDC for the gastric tumor cell lines.